Annexon, Inc.
ANNX evidence brief
What we can confirm
- BioSniper Score:
- 8.0 / 10
- Market Cap:
- $885.3M
- Lead Asset:
- ANX005 (Phase 3)
What it means
What to watch
Prepared research question
What matters most for ANNX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ANNX
Annexon, Inc. (ANNX) is a biopharmaceutical company developing targeted immunotherapies for neuroinflammatory diseases, with a lead program in geographic atrophy and Guillain-Barré syndrome.
Key risk: High net loss
BioSniper Score
Based on 4 of 6 signals
Market Cap
$885.3M
Cash Runway
—
Lead Asset
ANX005 (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 7 clinical trials for Annexon, Inc..
Annexon, Inc. (ANNX) is a biopharmaceutical company developing targeted immunotherapies for neuroinflammatory diseases, with a lead program in geographic atrophy and Guillain-Barré syndrome.
- Cash & equivalents of $199.3M as of 2026-06-30 [sec]
- Net income of -$55.3M for the quarter ended 2026-06-30 [sec]
- Phase 3 ARCHER II trial for vonaprument in geographic atrophy uses a dual primary endpoint at Months 15 and 24, with Month 15 results expected in Q4 2026 [news · 2026-08-12]
- BLA submission for vonaprument in Guillain-Barré syndrome expected in Q4 2026 [news · 2026-08-12]
- Phase 1 candidate ANX1502, an oral C1 inhibitor, is expected to deliver proof-of-concept data in Fall 2026 [news · 2026-08-12]
What works
- Vonaprument has received FDA Fast Track and EMA PRIME designations, indicating regulatory support for its development [news · 2026-08-24]
- The Phase 3 ARCHER II trial is the first pivotal trial designed to demonstrate protection of vision in geographic atrophy, with a consistent patient population [news · 2026-09-24]
- Annexon has a strong cash position of $199.3M as of 2026-06-30, providing runway for ongoing trials [sec]
What to weigh
- Net loss of $55.3M for the quarter ended 2026-06-30 reflects ongoing high R&D spending [sec]
- The Phase 3 ARCHER II trial faces a competitive landscape with 55 competitors, including Novartis and Astellas [pipeline]
- The dual primary endpoint design at Months 15 and 24 may delay final efficacy conclusions [news · 2026-08-12]
From the filings
Quoted directly from source documents.
Catalyst timeline
- 2020-09-29 · Phase 2 start for Huntington's disease (ANX005) — Initiation of a Phase 2a open-label study for ANX005 in Huntington's disease.
- 2020-12-17 · Phase 3 start for Guillain-Barré syndrome (ANX005) — Initiation of a randomized, double-blind, placebo-controlled Phase 3 study for ANX005 in GBS.
- 2021-11-10 · Phase 2 start for warm AIHA (ANX005) — Initiation of a Phase 2 open-label repeat dose study for ANX005 in warm autoimmune hemolytic anemia.
- 2024-07-30 · Phase 3 start for geographic atrophy (vonaprument) — Initiation of a Phase 3 multicenter, randomized trial for vonaprument in geographic atrophy.
Risks & what to watch (3)›
Key risks
- High net loss — Net loss of $55.3M in Q2 2026 indicates significant cash burn [sec]
- Competitive GA landscape — 55 competitors in geographic atrophy, including large pharma [pipeline]
- Dual endpoint delay — Month 24 endpoint may postpone final efficacy readout [news · 2026-08-12]
What to watch
- Month 15 primary endpoint results from ARCHER II expected in Q4 2026 [news · 2026-08-12]
- BLA submission for vonaprument in GBS expected in Q4 2026 [news · 2026-08-12]
- Proof-of-concept data for ANX1502 expected in Fall 2026 [news · 2026-08-12]
Sources: Catalysts · News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run Annexon, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Annexon, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.32 · 0% dilution
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
217
Total value held
$855.6M
| Holder | Shares | Value |
|---|---|---|
| redmile group, llc | 14,549,768 | $80.6M |
| blackrock, inc. | 10,938,509 | $60.6M |
| fmr llc | 10,635,648 | $58.9M |
| bvf inc/il | 8,698,173 | $48.2M |
| state street corp | 6,919,255 | $38.3M |
| vanguard capital management llc | 5,956,589 | $33.0M |
| bain capital life sciences investors, llc | 5,212,674 | $28.9M |
| bellevue group ag | 5,157,290 | $28.6M |
| mak capital one llc | 4,724,043 | $26.2M |
| adage capital partners gp, l.l.c. | 4,300,000 | $23.8M |
Showing top 10 of 217 institutional holders of Annexon, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 13.5%
- Days to cover
- 6.2
- Shares short
- 18,637,378
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ANNX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Annexon, Inc.?
Annexon, Inc. (ANNX) is a biopharmaceutical company developing targeted immunotherapies for neuroinflammatory diseases, with a lead program in geographic atrophy and Guillain-Barré syndrome.
What is Annexon, Inc.'s lead drug candidate?
Annexon, Inc.'s most advanced tracked candidate is ANX005 (Phase 3) for Warm Autoimmune Hemolytic Anemia (wAIHA); Huntington Disease; Guillain-Barre Syndrome.
Who is the CEO of Annexon, Inc.?
Mr. Douglas E. Love Esq., J.D. is the chief executive officer of Annexon, Inc. (ANNX).
Where is Annexon, Inc. headquartered?
Annexon, Inc. (ANNX) is headquartered in Brisbane, CA, United States.
What therapeutic areas does Annexon, Inc. focus on?
Annexon, Inc. develops therapies across Oncology, Rare Disease, Immunology, Ophthalmology, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.